This company listing is no longer active
Biotest (BIO3D) Stock Overview
Develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
BIO3D Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Biotest Aktiengesellschaft Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €32.00 |
| 52 Week High | €35.50 |
| 52 Week Low | €32.00 |
| Beta | 0.29 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | 60.00% |
| 5 Year Change | 31.96% |
| Change since IPO | 118.18% |
Recent News & Updates
Recent updates
Shareholder Returns
| BIO3D | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | 3.6% | 0.4% |
| 1Y | n/a | 37.2% | 19.9% |
Return vs Industry: Insufficient data to determine how BIO3D performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how BIO3D performed against the UK Market.
Price Volatility
| BIO3D volatility | |
|---|---|
| BIO3D Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 7.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: BIO3D has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine BIO3D's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1946 | 2,228 | Michael Ramroth | www.biotest.com |
Biotest Aktiengesellschaft develops, manufactures, and sells biological medicines in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in hematology, clinical immunology, and intensive care medicine areas.
Biotest Aktiengesellschaft Fundamentals Summary
| BIO3D fundamental statistics | |
|---|---|
| Market cap | €1.46b |
| Earnings (TTM) | -€47.20m |
| Revenue (TTM) | €517.40m |
Is BIO3D overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIO3D income statement (TTM) | |
|---|---|
| Revenue | €517.40m |
| Cost of Revenue | €394.00m |
| Gross Profit | €123.40m |
| Other Expenses | €170.60m |
| Earnings | -€47.20m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
Aug 10, 2023
| Earnings per share (EPS) | -1.19 |
| Gross Margin | 23.85% |
| Net Profit Margin | -9.12% |
| Debt/Equity Ratio | 185.4% |
How did BIO3D perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/06/26 19:52 |
| End of Day Share Price | 2023/03/29 00:00 |
| Earnings | 2023/03/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Biotest Aktiengesellschaft is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Torben Teichler | Hauck Aufhäuser Investment Banking |
| Jan Keppeler | HSBC |
| Dennis Berzhanin | Pareto Securities |